Across the recent three months, 10 analysts have shared their insights on Harmony Biosciences HRMY, expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 4 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $48.2, a high estimate of $53.00, and a low estimate of $40.00. Surpassing the previous average price target of $42.67, the current average has increased by 12.96%.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of Harmony Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ami Fadia | Needham | Maintains | Buy | $50.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $49.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $50.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $50.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $49.00 | - |
| Graig Suvannavejh | Mizuho | Lowers | Buy | $40.00 | $42.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $49.00 | - |
| Ami Fadia | Needham | Lowers | Buy | $50.00 | $53.00 |
| Ami Fadia | Needham | Maintains | Buy | $53.00 | - |
| Graig Suvannavejh | Mizuho | Raises | Buy | $42.00 | $33.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Harmony Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Harmony Biosciences compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
To gain a panoramic view of Harmony Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Harmony Biosciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Harmony Biosciences: A Closer Look
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Understanding the Numbers: Harmony Biosciences's Finances
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Harmony Biosciences displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 31.26%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Harmony Biosciences's net margin excels beyond industry benchmarks, reaching 15.8%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Harmony Biosciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.61%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Harmony Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.35% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Harmony Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.41, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
